Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Leukemia, Promyelocytic, Acute 1Breast Neoplasms 1

Interventions

pembrolizumab 550Specimen Handling 462Carboplatin 441Magnetic Resonance Spectroscopy 429Cyclophosphamide 412Cisplatin 398Radiotherapy 313Gemcitabine 310Bevacizumab 306Paclitaxel 294Biopsy 259Drug Therapy 248Capecitabine 241Oxaliplatin 239fludarabine 238Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 202Dexamethasone 186Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 145durvalumab 143Leucovorin 138atezolizumab 137toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × arsenous acid × Clear all
NCT01409161 2026-05-20

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
151 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06678048 2025-06-06

Arsenous Acid for Refractory Triple-Negative Breast Cancer

Sun Yat-sen University

Phase 2 Recruiting
12 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡